Lancet Dia& Endo:二甲双胍预处理对无糖尿病患者冠状动脉搭桥术后心肌损伤的影响

2015-07-13 MedSci译 MedSci原创

    在冠状动脉旁路移植术(CABG)过程中,局部缺血和再灌注会损伤心肌组织,增加术后血浆肌钙蛋白浓度,这些都会导致较差的预后。研究人员调查了在非糖尿病患者CABG手术中,二甲双胍预处理是否可以限制心肌损伤,由肌钙蛋白所浓度进行评估。    研究人员在奈梅亨(荷兰)大学医院对非糖尿病选择体外循环冠状动脉搭桥术成人患者做了这项安慰剂对照,双盲,单中心研究。通

在冠状动脉旁路移植术(CABG)过程中,局部缺血和再灌注会损伤心肌组织,增加术后血浆肌钙蛋白浓度,这些都会导致较差的预后。研究人员调查了在非糖尿病患者CABG手术中,二甲双胍预处理是否可以限制心肌损伤,由肌钙蛋白所浓度进行评估。

研究人员在奈梅亨(荷兰)大学医院对非糖尿病选择体外循环冠状动脉搭桥术成人患者做了这项安慰剂对照,双盲,单中心研究。通过计算机生成的随机序列10块随机分配患者(1:1)在手术前(每天三次)3天接受二甲双胍盐酸盐(每天500毫克三次)或安慰剂。最后一次剂量给予手术前约3小时。患者,调查人员,试验人员和统计学家都不知道治疗分配。主要终点是血浆超敏感肌钙蛋白I在手术后再灌注后6,12,和24小时的浓度,在符合方案人群中使用所有这些时间点的混合模型分析。次要终点包括再灌注后24小时内与临床相关性心律失常,强心剂的需要,拔管时间,留在重症监护病房的时间,术后胰岛素的使用。

在2011年11月8日和2013年11月22日之间,研究人员随机分配111例患者治疗(57例接受二甲双胍和54接受安慰剂)。二甲双胍组5例患者退出,安慰剂组6例退出。二甲双胍组52例患者和安慰剂组48例被纳入符合分析的人群。在再灌注后6小时时,二甲双胍组高灵敏度肌钙蛋白I的几何平均值从0微克/升增加到3.67微克/升(95%Cl 3.6-4.41),安慰剂组上升到3.32微克/升(2.75-4.01 );在12小时分别为2.84微克/升(2.37-3.41),2.45微克/升(2.02-2.96);在24小时分别为1.77微克/升(1.47-2.12)和1.60微克/升(1.32-1.94)。该浓度没有显著组间差异(所有时间点差异为12.3%[95%Cl -12.4至44.1] P =0.35)。心律失常的发生没有组间差异(二甲双胍组有3例[5.8%] vs 安慰剂组3例[6.3%];P=1.00)。在需要强心剂方面,拔管时间,在重症监护病房停留时间,或术后使用胰岛素情况组间无差异。手术后30天内无死亡病例。二甲双胍组胃肠不适(主要是腹泻)的发生率显著高于比安慰剂组(11[21.2%] vs 2[4.2%];P=0.01)。

短期二甲双胍预处理,虽然安全,但似乎没有成为减少无糖尿病冠状动脉搭桥手术患者围手术期心肌损伤的一个有效的策略。

原始出处:
Saloua El Messaoudi, MD, Rianne Nederlof, MSc, Coert J Zuurbier, PhD, Prof Henry A van Swieten, MD, Prof Peter Pickkers, MD, Luc Noyez, MD, Hendrik-Jan Dieker, MD, Marieke J Coenen, PhD, A Rogier T Donders, PhD, Annemieke Vos, Prof Gerard A Rongen, MD, Prof Niels P Riksen, MDcorrespondenceemail,Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes ,Lancet,2015.7.12

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
    2015-08-04 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1637128, encodeId=1680163e1283f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 29 02:18:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663889, encodeId=cc72166388910, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Aug 02 09:18:00 CST 2015, time=2015-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828176, encodeId=48e318281e63a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 04 06:18:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310039, encodeId=8b39131003959, content=<a href='/topic/show?id=ddd95126e4e' target=_blank style='color:#2F92EE;'>#心肌损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51267, encryptionId=ddd95126e4e, topicName=心肌损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396924, encodeId=8347139692487, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473875, encodeId=3cb014e387501, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492351, encodeId=2a3a149235101, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Wed Jul 15 06:18:00 CST 2015, time=2015-07-15, status=1, ipAttribution=)]
    2015-07-15 zzc2214

相关资讯

我的设计我做主:MedSci临床研究方案设计活动(第二轮)-立题公布(1)

任务目标:完成一份辅助生殖相关的临床研究设计 在发布的立题选项中,看下方 任务一(2015.7.6发布):临床研究立题(方向) 请各位从以下研究立题中选择一个,开展后续的研究设计任务: A. 卵巢低反应对于IVF妊娠结局的影响 B. OHSS发生的相关风险因素 C. XX激素水平(或者其他biomarker指标)是否可以预测IVF妊娠结局 D. 两种促排方

The Lancet Diabetes & Endocrinology:二甲双胍不应被用来改善无糖尿病的肥胖女性的妊娠结局

产妇肥胖与婴儿体重上升相关,而肥胖又与成年子女过早死亡有关。母体肥胖导致这些结果的机制还不是很清楚,但产妇的高血糖是和胰岛素抵抗密切相关的。该研究目的是研究胰岛素增敏药物二甲双胍是否能改善无糖尿病但肥胖的孕妇和胎儿的结局。       研究人员在英国15个国家的卫生服务医院的产前检查诊所做了这项随机、双盲、安慰剂对照试验。参与者为12和16周妊娠期

Lancet:二甲双胍不能改善晚期胰腺癌患者的治疗结果

背景:在临床前工作和回顾性人群研究中,抗糖尿病药物二甲双胍已证实与抗肿瘤活性和降低许多癌症(包括胰腺癌)的负担有关。因此假设这种药物可以用来作为肿瘤指示。该研究的目的是评估将二甲双胍加入到一个标准系统治疗晚期胰腺癌的治疗后的疗效,并提供一个肿瘤显示二甲双胍生存终点的临床实验的第一报告。    方法:研究人员在荷兰的四个中心做了这项双盲、随机、安慰剂对照的Ⅱ期临床试验。

PLoS One:二甲双胍对妊娠糖尿病治疗是有效的

目前“二甲双胍”成了治疗妊娠期间的糖尿病孕妇的”“新宠”,很多研究纷纷涌现该领域,因为其相比于胰岛素,安全性可靠,价格更实惠,操作更方便,患者的痛楚也更小。而胰岛素作为既往该治疗领域的龙头老大,能否稳坐“座山雕”的位置临床界也是拭目以待。关于妊娠期间的糖尿病有两种情况,一种为妊娠前已确诊患糖尿病,称“糖尿病合并妊娠”;另一种为妊娠前糖代谢正常或有潜在糖耐量减退、妊娠期才出现或确诊的糖尿病,又称为“

Lancet Diab & Endo:二甲双胍增加终末期肾病病死率

     背景及目的:二甲双胍是T2DM的一线用药,一直以来,因为可能增加乳酸酸中毒的风险,一直禁用于肾功能不全患者。目前研究证据表明,在轻到中度慢性肾脏病患者中,可以慎用二甲双胍。然而,目前尚缺乏有关评估严重慢性肾脏病患者使用二甲双胍的证据。本研究旨在评估二甲双胍在T2DM合并进展期慢性肾脏病(大约CAD-5期)的安全性。 方法:我们在台湾国民健康研究数据库中

Lancet:对于晚期慢性肾病患者,不提倡使用二甲双胍

背景:二甲双胍被推荐为2型糖尿病患者的一线治疗方法。然而,这种药物已被禁用于肾功能受损的患者,因为有乳酸性酸中毒的风险。目前的证据支持有轻度至中度慢性肾脏病患者治疗时谨慎使用。然而,目前缺乏对于晚期慢性肾脏病患者使用二甲双胍的研究。该研究的目的是评估2型糖尿病合并晚期慢性肾脏病患者使用二甲双胍的安全性(约5期)。    方法:研究人员在2000年1月1日和2009年6